Side alternating vibration training in patients with mitochondrial disease: a pilot study

dc.contributor.authorNewell, Christopher
dc.contributor.authorRamage, Barbara
dc.contributor.authorRobu, Ion
dc.contributor.authorShearer, Jane
dc.contributor.authorKhan, Aneal
dc.date.accessioned2018-11-07T17:09:44Z
dc.date.available2018-11-07T17:09:44Z
dc.date.issued2017-08-08
dc.date.updated2018-11-07T17:09:44Z
dc.description.abstractAbstract Background Side alternating vibration training (SAVT) is a mechanical oscillation using a vibrating platform that simulates exercise. We hypothesized that patients with mitochondrial myopathies, who experience muscle weakness, may see an improvement in muscle power with SAVT. Methods Patients with mitochondrial disease started either a treatment (SAVT) or control phase (standing without vibration) for 12 weeks, then 12 weeks of washout, and then a 12-week cross-over. The main outcome measure was peak jump power (PJP). We compared this to a natural history cohort from clinic. Results Seven out of 13 patients completed at least 80% of their SAVT sessions and were analyzed. The ΔPJP after the control phase was −2.7 ± 1.7 W/kg (mean ± SEM), SAVT was +2.8 ± 0.6 W/kg (p < 0.05) and from the natural history cohort was −2.4 ± 0.8 W/kg/year. Conclusions SAVT is well tolerated and may improve muscle power in mitochondrial disease patients.
dc.identifier.citationArchives of Physiotherapy. 2017 Aug 08;7(1):10
dc.identifier.doihttps://doi.org/10.1186/s40945-017-0038-4
dc.identifier.urihttp://hdl.handle.net/1880/109110
dc.identifier.urihttps://doi.org/10.11575/PRISM/45258
dc.language.rfc3066en
dc.rights.holderThe Author(s).
dc.titleSide alternating vibration training in patients with mitochondrial disease: a pilot study
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
40945_2017_Article_38.pdf
Size:
364.36 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description: